A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study aims to assess patient characteristics and treatment patterns of second-line systematic therapies, including BRAF V600E mutation-guided dabrafenib plus trametinib (D+T) and MKIs, among Chinese adult patients with RAI-R DTC. This is a non-interventional study using secondary data derived from a real-world Electronic Health Record (rEHR) database in China.
Epistemonikos ID: 0585a8088ae74a4332f1f27a7aaf5dee458e65f2
First added on: Aug 19, 2026